OneTwenty AG

OneTwenty revolutionizes Diabetes Care and the live of 500m

Today, 500m people with diabetes still life in constant stress, tension and danger despite modern technology. OneTwenty's Machine Learning system has been developed to solve this and give back health and peace of mind to people. The technology is integrated in existing medical devices like insulin pumps or insulin pens and controls insulin dosing based on self-learning, individualized models for each user and with a very short start-up phase. Our B2B business model is to license the solution to market-leading medtech companies and therefore revolutionize their product offering. Win-win-win. Beyond diabetes, this technology can be applied to countless fields of diseases to improve digital therapeutics and medical hardware.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
REGISTER
Deal

01.08.2024

Contract signed with market leading sensor and wearable company

Deal

31.07.2024

ISO 13485 certification received

Deal

01.04.2024

First deal with market leading medtech and diabetes tech client

Milestone

19.12.2023

First financing round

Deal

01.09.2022

bioX® neoAP is externally benchmarked, delivers market-leading results and is being integrated by first innovative medtech companies

Show more...

No Jobs

No videos and documents

No Awards

OneTwenty AG

OneTwenty revolutionizes Diabetes Care and the live of 500m

Website:
onetwenty.ai

Headquarter:
Zürich

Foundation Date:
January 2022

Technology:

  • Medtech

Sectors:

  • Bioinformatics
  • Digital Health
  • Machine Learning / AI
  • Medical devices
  • Medtech
  • Services for companies

Support received

  • Support venture leaders